{ "schemaVersion": "deck-intelligence.v1", "id": "019de075-dd1e-7468-9323-d12fde1b7732", "slug": "a9cc0c508d45d8985f57408ace49b969", "title": "RayzeBio | IPO Presentation Deck | 41 slides", "subtitle": "RayzeBio · 2023-09", "author": "RayzeBio", "date": "2023-09-01 00:00:00", "pageCount": 41, "kind": "pitchdeck", "orientation": "landscape", "aspectRatio": 1.7761332, "document": { "id": "019de075-dd1e-7468-9323-d12fde1b7732", "slug": "a9cc0c508d45d8985f57408ace49b969", "title": "RayzeBio | IPO Presentation Deck | 41 slides", "rawTitle": "RayzeBio | IPO Presentation Deck | 41 slides", "authorId": "rayzebio", "authorName": "RayzeBio", "authorDisplay": "RayzeBio", "kind": { "slug": "pitchdeck", "label": "Pitch deck" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2023-09__rayzebio__ipo__a9cc0c50.pdf", "sourceUrl": "https://www.slidebook.io/company/rayzebio/presentation/a9cc0c508d45d8985f57408ace49b969/", "sourceDate": "2023-09-15 00:00:00", "presentationDate": "2023-09-01 00:00:00", "ingestedAt": "2026-04-30 22:15:14.127064+00", "status": "ready", "pageCount": 41, "orientation": "landscape", "aspectRatio": 1.7761332, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "drug-manufacturers-specialty-generic", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-09__rayzebio__ipo__a9cc0c50", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 41, "pagesIndexed": 41, "pagesWithImages": 41, "pagesWithMetadata": 41, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 177, "chartCount": 12, "metricSlides": 0, "toolMatches": 15, "documentToolMatches": 0, "frameworkMatches": 16, "arcMatches": 1, "beatMatches": 4, "loopMatches": 3, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "evidence": "The document follows a structured narrative, similar to the Sequoia Pitch, with sections on problem, solution, market sizing, and team.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:37:55.404617+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Problem", "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 22, "name": "Market Sizing", "beatId": "4eb5bdc2-46df-4e7d-90bc-1dad24a39c2b", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The document provides market sizing information for RYZ101 in GEP-NETS.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 39, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 39, "name": "Team", "beatId": "b1b90c07-22d7-4572-9e13-314d9970d9bb", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The document presents information about RayzeBio's experienced and entrepreneurial life sciences team.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "53cf3362-2492-4fd7-a1a1-affed636c3a5", "evidence": "The document highlights the unmet need in NETs and the potential market opportunity.", "position": 0, "objective": "What is the cost of inaction in addressing the unmet need in NETs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.580626+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 11, "from": 10, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "993d8b01-aa58-414e-8912-0e3cffca5321", "evidence": "The document presents the current market trends and growth opportunity in radiopharmaceuticals.", "position": 1, "objective": "Why is now the right time for RPTs in cancer treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.617297+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null, "categoryName": "Consulting Framework", "categorySlug": "consulting-framework" }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "51c9b069-d447-4d68-91cb-a5c088352173", "evidence": "title/headline: Corporate Presentation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.112953+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4d8e84dc-409f-473c-b436-a9e9112af641", "evidence": "table/data: Issuer (Exchange / Ticker): RayzeBio, Inc. (NASDAQ / RYZB) Base offering size: 14,398,000 shares Share composition: Primary: 13,235,000 shares; Secondary: 1,163,000 shares Overallotment option: 2,159,700 shar", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.244785+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "19ee6028-2780-42bf-bdb5-710b83a24089", "evidence": "title/headline: RayzeBio – A Leader in Radiopharmaceutical Therapies (RPT)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.324766+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c62bbe63-e8da-4211-9c57-92da1f327155", "evidence": "list/bullet: RYZ101 in late line GEP-NETs presents significant market opportunity; No approved drugs post 177Lu setting; SSTR2 expression in ES-SCLC; RYZ101 drug protection; Life cycle management with novel SSTR2 binder", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:16.407863+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2639f27c-3478-4807-8e48-f5dcf87b5440", "evidence": "Swimmer plot showing patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:21.312195+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e85c7541-e7f4-4f5a-9f79-a7e31dd4d178", "evidence": "Comparison table between Lutathera and RYZ101", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:21.386474+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1f1cde42-58e3-46d8-afbf-74acb80993c5", "evidence": "List of Key Eligibility Criteria", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:21.461411+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0b15f38-17e3-4bba-85e2-268a7cb2b6bc", "evidence": "Addressable Patient Population", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:32:21.536378+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Figure-Ground Relationship", "slug": "figure-ground-relationship", "status": "active", "bestFor": null, "canonId": "019dd956-d087-741f-b358-1303dd35483e", "version": 1, "bodyDocId": null, "description": "Perception organizes into figure (focus) and ground (background)", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "ead18fee-1850-4cb1-b6d7-c5fcae7e2142", "evidence": "SSTR2 expression appears to be distinct from DLL3 expression in SCLC tumors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:32:21.609234+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "69213300-7ea1-46ca-be72-03beba61b9da", "evidence": "Target patient population: extensive stage small cell lung cancer (ES-SCLC)", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:32:21.759166+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "HFS Horizons", "slug": "hfs-horizons", "status": "active", "bestFor": null, "canonId": "019de52d-1a8a-70de-a683-cfc294ece899", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2b9f34c1-0ee0-4735-8ff4-3201f53b6c81", "evidence": "Novel SSTR2 binder opportunities: Extend revenue opportunity for RYZ101 in additional indications", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:32:21.834048+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Information architecture", "slug": "information-architecture", "status": "active", "bestFor": null, "canonId": "643f994f-1fa5-4c17-8dfe-aa33e091b6aa", "version": 1, "bodyDocId": null, "description": "Wayfinding, scannability, scent, F-pattern, banner blindness.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1547f501-0560-4aea-854b-9c702c63ae0f", "evidence": "63,000 sq. ft. facility in Indianapolis; Designed to support development and commercial scale manufacturing", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:21.908321+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": "optional", "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d8b4a52d-ebfb-4382-94ce-8b280d237c3a", "evidence": "Target Selection -> Binder discovery and optimization -> In vitro screening -> X-ray crystallography -> Linker exploration and optimization -> Radiolabeling optimization -> In vivo screening", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:21.984249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0ba7743c-6153-41d4-97c3-92c2a5250828", "evidence": "chart/waterfall: Best Tumour Shrinkage (per RECIST v1.1)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:10.850323+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "16692f74-b4d9-494d-bdc5-442458cc81bb", "evidence": "framework/instance: Gantt chart style roadmap", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:11.156322+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "09fb1c59-c660-48bd-8988-e8a7e794ca2d", "evidence": "The pipeline visualization uses horizontal bars to represent progress across development stages.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" }, { "matchId": "15dcfd30-5d5a-44f5-90bf-ca28f1d0c212", "evidence": "Direct visual and textual comparison between two medical modalities.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "comparison-frame" }, { "matchId": "2e2de58d-54b7-4fa8-a516-32aea2d50cd2", "evidence": "Side-by-side comparison of Efficacy and Safety categories", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison_frame" }, { "matchId": "01564305-50e9-46ba-b7e2-03138b0660b9", "evidence": "Direct comparison of alpha and beta radiation properties and effects", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" }, { "matchId": "97e4b886-4a4a-4eec-86c0-5c93d7788fb5", "evidence": "Chronological progression of cancer treatment modalities", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "timeline" }, { "matchId": "b692bd2c-78d9-4429-8770-96a774fab7a2", "evidence": "Side-by-side comparison of two products across key metrics", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison-frame" }, { "matchId": "a09cd407-62e9-475a-bb66-ad3b9aa09e53", "evidence": "The slide uses a flow chart to depict the clinical treatment pathway for NET patients.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:22.241+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" }, { "matchId": "f8bcedb8-8af0-49a1-9958-5d706f17d1b0", "evidence": "Contrasts current clinical success with the inevitable future state of disease progression.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "before-after-framing" }, { "matchId": "9576f9cf-fea9-43f0-831d-194cfbdf36c3", "evidence": "Standard clinical trial efficacy visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "waterfall-plot" }, { "matchId": "0088f4dc-c621-4378-af4d-4ef2f5af097c", "evidence": "Direct side-by-side comparison of product attributes to highlight competitive advantage.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" }, { "matchId": "0b1797e5-d20c-4c4d-befb-317fa0500738", "evidence": "Standardized flow of patient population to treatment arms and endpoints", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "clinical-trial-design" }, { "matchId": "a4e6851d-00d0-40f2-858e-3eaafd0a1b2a", "evidence": "Sequential workflow diagram", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "process" }, { "matchId": "a577a4ba-f57a-4f38-8229-91f097c4bb98", "evidence": "Staircase diagram showing sequential development stages", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:21.943+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "process" }, { "matchId": "f2b4c7fa-9233-4ea1-88c3-2a86a477963e", "evidence": "The slide uses a flow diagram to show the sequence of clinical development steps.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:22.771+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "process" }, { "matchId": "010a8748-543d-43e6-a621-f8ad8df4b31f", "evidence": "Timeline-based project management visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:22.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "gantt-chart" }, { "matchId": "367b7cdf-c650-4242-814a-8fce22db400b", "evidence": "The slide maps the company's activities from discovery to manufacturing as a vertical integration strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 40, "frameworkName": "value-chain" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/WwaHMByhLYOdGsqVSy1Sq6y9unOhUWfsfyqAhmHdLjs/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hOWNjMGM1MDhkNDVkODk4NWY1NzQwOGFjZTQ5Yjk2OS9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 3, "textChars": 44, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.248+00", "seconds": 4.498, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/1", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-1", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.38, "x": 0.31, "y": 0.295 }, "kind": "image", "text": "RayzeBio", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "add50fb9-b756-45cd-a856-cf9f76f38073", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.18, "x": 0.41, "y": 0.74 }, "kind": "paragraph", "text": "September 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4b743f1b-e0cd-40f4-8e0b-39efdc134d64", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.34, "x": 0.33, "y": 0.6 }, "kind": "title", "text": "Corporate Presentation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.248+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3087ecae-52c5-4195-a45d-d04629263e04", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "51c9b069-d447-4d68-91cb-a5c088352173", "evidence": "title/headline: Corporate Presentation", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.112953+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/BzbgEpyOXjwWo0XiDK4lYsYzrgyqBV1ajyDOUcUTbEM/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hOWNjMGM1MDhkNDVkODk4NWY1NzQwOGFjZTQ5Yjk2OS9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/ed7LxKZZTq-3pNL-_p7gU7H7aIoGUPwAbc2OL8R2D9c/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hOWNjMGM1MDhkNDVkODk4NWY1NzQwOGFjZTQ5Yjk2OS9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/tSfsnk5d1DIAT4ZzwFrDlFDOZnMnLMMemp7SMlJgh4E/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy9hOWNjMGM1MDhkNDVkODk4NWY1NzQwOGFjZTQ5Yjk2OS9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "other", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 135, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:18.098+00", "seconds": 1.92, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/2", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-2", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "disclaimer", "text": "This presentation and any accompanying oral commentary have been prepared by RayzeBio, Inc. ...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:18.098+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "054780b9-513d-4854-87f7-919a139e2474", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Forward Looking Statements & Disclaimers", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:18.098+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4d2e7426-1f9a-4dac-9403-2a2276a8853c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "resolution", "title": "This is a standard IPO/follow-on offering summary table.", "function": "plan_implementation", "rawType": "use_of_funds", "block": null, "metadata": { "slideType": "use_of_funds", "slideTypeCanon": { "name": "Use of funds", "slug": "use_of_funds", "status": "active", "canonId": "019de52d-1045-737c-90e9-c79600f9e2c7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 26, "componentCount": 2, "textChars": 255, "nDataPoints": 12, "notes": "This is a standard IPO/follow-on offering summary table.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:18.584+00", "seconds": 2.388, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/3", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-3", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.94, "x": 0.03, "y": 0.15 }, "kind": "table", "text": "Issuer (Exchange / Ticker): RayzeBio, Inc. (NASDAQ / RYZB) Base offering size: 14,398,000 shares Share composition: Primary: 13,235,000 shares; Secondary: 1,163,000 shares Overallotment option: 2,159,700 shares Price range: $16.00 - $18.00", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:18.584+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e953988-8f19-42f4-9365-f0b3834246d0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Offering summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:18.584+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c048f4f0-bf0c-4a6a-a0d5-4b211ff23ba5", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Table data", "slug": "table-data", "status": "active", "bestFor": null, "canonId": "019dd9e1-4fab-7168-a82f-b847350a006d", "version": 1, "bodyDocId": null, "description": "Tabular layouts of structured data.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "4d8e84dc-409f-473c-b436-a9e9112af641", "evidence": "table/data: Issuer (Exchange / Ticker): RayzeBio, Inc. (NASDAQ / RYZB) Base offering size: 14,398,000 shares Share composition: Primary: 13,235,000 shares; Secondary: 1,163,000 shares Overallotment option: 2,159,700 shar", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.244785+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 3, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide uses a structured table format to present key company metrics and status.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 287, "nDataPoints": 6, "notes": "The slide uses a structured table format to present key company metrics and status.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.307+00", "seconds": 4.956, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/4", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-4", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.8, "x": 0.03, "y": 0.91 }, "kind": "disclaimer", "text": "Isotopes used in preclinical and clinical studies have partly been supplied by the U.S. Department of Energy Isotope Program, managed by the Office of Isotope R&D and Production", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf411a35-e0db-42ad-aeac-3e6e46c2e969", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.8, "x": 0.15, "y": 0.75 }, "kind": "image", "text": "Investor logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "15cf123b-41af-4791-8a64-57760b0a5262", "parentComponentId": null }, { "bbox": { "h": 0.72, "w": 0.94, "x": 0.03, "y": 0.17 }, "kind": "table", "text": "Focus, Pipeline, Other Assets, Capital", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1b266303-7e02-4e50-ba2a-6f78688dcd4b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RayzeBio – A Leader in Radiopharmaceutical Therapies (RPT)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.307+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "699afa2c-58a0-436d-b68c-d623145960f6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "19ee6028-2780-42bf-bdb5-710b83a24089", "evidence": "title/headline: RayzeBio – A Leader in Radiopharmaceutical Therapies (RPT)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:16.324766+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "resolution", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 74, "componentCount": 7, "textChars": 613, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:24.067+00", "seconds": 7.593, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/5", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-5", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.28, "x": 0.03, "y": 0.58 }, "kind": "callout", "text": "Blockbuster Potential with GPC3 or Other programs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d70eaf5-1f3a-42ef-8834-ba2873844af4", "parentComponentId": null }, { "bbox": { "h": 0.38, "w": 0.28, "x": 0.03, "y": 0.14 }, "kind": "callout", "text": "SSTR2 – Potential Market leading sustainable franchise", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6ab618ba-97ec-45ae-91cf-06b83f306248", "parentComponentId": null }, { "bbox": { "h": 0.18, "w": 0.94, "x": 0.03, "y": 0.78 }, "kind": "callout", "text": "World-class Capabilities and Infrastructure", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c94333b3-004e-47c0-a67a-e1846af07c6c", "parentComponentId": null }, { "bbox": { "h": 0.38, "w": 0.66, "x": 0.31, "y": 0.14 }, "kind": "list", "text": "RYZ101 in late line GEP-NETs presents significant market opportunity; No approved drugs post 177Lu setting; SSTR2 expression in ES-SCLC; RYZ101 drug protection; Life cycle management with novel SSTR2 binder", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a46db965-c677-4b63-87d0-6363e172cba6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.66, "x": 0.31, "y": 0.81 }, "kind": "list", "text": "Industry leading knowledge on 225Ac; Supply agreements for 225Ac; Commercial scale RayzeBio centralized GMP facility", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b9ca17fa-3aa3-4671-bfc7-604b0bae16a3", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.66, "x": 0.31, "y": 0.58 }, "kind": "list", "text": "RYZ801 targeting GPC3 (liver cancer); 41,000 new liver cancer expected in the U.S. in 2023; Additional discovery programs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e4575b50-f61b-4465-a6e5-86bb4f97b161", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Product Focused Approach", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.067+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb2f4be1-b1dc-4e83-9403-d9a94235eb46", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "c62bbe63-e8da-4211-9c57-92da1f327155", "evidence": "list/bullet: RYZ101 in late line GEP-NETs presents significant market opportunity; No approved drugs post 177Lu setting; SSTR2 expression in ES-SCLC; RYZ101 drug protection; Life cycle management with novel SSTR2 binder", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:16.407863+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a Gantt-style visualization for drug development stages.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 409, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization for drug development stages.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.696+00", "seconds": 3.138, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/6", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-6", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.07, "w": 0.258, "x": 0.527, "y": 0.635 }, "kind": "callout", "text": "With RPT, compassionate use is possible prior to IND filing", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ed0b7832-fde4-4343-97cf-015d9b8e6566", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.45, "x": 0.3, "y": 0.25 }, "kind": "chart", "text": "Horizontal bars representing the development progress of drug candidates.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09cefa07-422a-41ff-9546-b591d1ea925c", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.85 }, "kind": "source-note", "text": "Footnotes detailing GEP-NETs, clinical trial data, and compassionate use definitions.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87e78973-a57d-40b2-a41c-399a076ee010", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.9, "x": 0.05, "y": 0.17 }, "kind": "table", "text": "Pipeline table with columns for Target, Drug, Indication, Discovery, IND Enabling, Phase 1, Phase 2, Phase 3, and Next Anticipated Milestone.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e312d25-043d-4310-aef2-e6150edc4bb4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RayzeBio Radiopharmaceutical Therapy (RPT) Pipeline", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50f45dbc-d80c-449a-9752-d3193cb94d6a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "09fb1c59-c660-48bd-8988-e8a7e794ca2d", "evidence": "The pipeline visualization uses horizontal bars to represent progress across development stages.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.696+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "setup", "title": "Uses a visual metaphor of 'Outside in' vs 'Precise from within' to contrast the two treatment modalities.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 6, "textChars": 595, "nDataPoints": 0, "notes": "Uses a visual metaphor of 'Outside in' vs 'Precise from within' to contrast the two treatment modalities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.144+00", "seconds": 3.548, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/7", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-7", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.28, "x": 0.43, "y": 0.43 }, "kind": "image", "text": "Diagram showing RPT (via injection) targeting multiple tumor sites from within the body.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9e38f3bb-e544-447d-a961-dab7aab7db6b", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.28, "x": 0.06, "y": 0.43 }, "kind": "image", "text": "Diagram showing External Beam radiation targeting a single tumor area from outside the body.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b17a3e73-b33e-4c33-a9b1-3d58de4e97a6", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.25, "x": 0.73, "y": 0.48 }, "kind": "list", "text": "Mitigating Radiation Exposure: Radiation delivered more selectively to tumors mitigating off target toxicity.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3e5178a6-fed4-42dc-8b1b-bedc68babfcd", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.25, "x": 0.73, "y": 0.00175 }, "kind": "list", "text": "Potency: RPT can treat systemic disease which external beam cannot; RPT delivers more potent types of radiation (alpha, beta) as compared to photons from external beam.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "46a7ecad-98de-4f8c-aa43-219f8b39ffdd", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.25, "x": 0.73, "y": 0.75 }, "kind": "list", "text": "Convenience: RPT typically delivered in fewer cycles (fractions).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aaa14059-f47a-4e2f-82d4-d7323ab039cc", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "Radiopharmaceutical Therapy (RPT) – Building on Benefits of External Beam", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c5308410-e59a-4c0f-b5e4-241bbab656ad", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "15dcfd30-5d5a-44f5-90bf-ca28f1d0c212", "evidence": "Direct visual and textual comparison between two medical modalities.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:20.144+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "comparison-frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "setup", "title": "The slide uses a simple comparison framework to highlight clinical benefits.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 6, "textChars": 558, "nDataPoints": 0, "notes": "The slide uses a simple comparison framework to highlight clinical benefits.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.486+00", "seconds": 6.88, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/8", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-8", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.325 }, "kind": "callout", "text": "RPT Has Advantages that May Offer Efficacy and Safety Benefits over ADCs", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56120efa-105d-47a7-b9a4-8a1a3bff03d8", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.52, "y": 0.55 }, "kind": "list", "text": "Precision medicine with RPT imaging allows for better patient selection; Dosimetry helps determine maximum safe dose; RPTs utilize stable linker thus minimizing premature release of payload", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4848953a-3ac4-4625-97ef-6d47047d391f", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.05, "y": 0.55 }, "kind": "list", "text": "Radioisotope payload is orders of magnitude more potent than ADC chemo payload; RPT kills cells regardless of cellular internalization; RPTs can avoid drug resistance mechanisms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cdc86ecf-f3ce-45e2-af5c-d0fdffe42fd0", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.58, "x": 0.21, "y": 0.215 }, "kind": "paragraph", "text": "RPT and ADCs are conceptually similar (binder + linker + payload)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "53721beb-8fb4-4266-b742-be1206cc9199", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.94, "x": 0.03, "y": 0.43 }, "kind": "table", "text": "Efficacy vs Safety comparison", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5391fbfd-db3f-4f16-aa23-1c26e72d32b8", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RPT – Advantages over ADCs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1f6727a-7ee1-4249-b565-ae24cc8b8b12", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "2e2de58d-54b7-4fa8-a516-32aea2d50cd2", "evidence": "Side-by-side comparison of Efficacy and Safety categories", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:23.486+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 8, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 9, "type": "tension", "title": "The slide uses a comparison framework to justify the use of alpha-emitting isotopes in targeted radiotherapy.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 646, "nDataPoints": 6, "notes": "The slide uses a comparison framework to justify the use of alpha-emitting isotopes in targeted radiotherapy.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.037+00", "seconds": 3.284, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/9", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-9", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.09, "w": 0.94, "x": 0.03, "y": 0.16 }, "kind": "callout", "text": "Alpha radiation causes direct, irreparable double-stranded DNA breaks compared with beta radiation, which typically cause single-stranded breaks via indirect DNA damage", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d52ea826-be97-431a-b626-962981d94bbe", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.52, "y": 0.3 }, "kind": "image", "text": "Visual representation of alpha vs beta radiation hitting DNA strands", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d4ce7eb6-cf6d-47cb-91ea-baa6b8945a65", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.03, "y": 0.28 }, "kind": "list", "text": "225Actinium (225Ac), 223Radium: 2 protons + 2 neutrons; Up to 400 times more damaging than β isotopes, linear energy transfer (keV/um): ~80-100; Causes double stranded DNA breaks; Tissue range: 20 to 80 um", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c7b1a67d-0dbd-43c2-bd86-faea6edef93c", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.03, "y": 0.6 }, "kind": "list", "text": "177Lutetium (177Lu), 131Iodine: Electron particle; Linear energy transfer (keV/um): ~0.2-0.5; Causes mostly single stranded DNA breaks; Tissue range: 2 to 11.5 mm", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5d90fe7-5394-4a71-9ad4-7076c9246303", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.5, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "Alpha (α) and Beta (β) Isotopes Disrupt DNA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ee119b3-34ad-4925-a8db-ed09d3f35fc4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "01564305-50e9-46ba-b7e2-03138b0660b9", "evidence": "Direct comparison of alpha and beta radiation properties and effects", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:20.037+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "frameworkName": "comparison-frame" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "setup", "title": "The slide uses a chronological progression of therapeutic classes (Targeted, Immuno-oncology, ADCs, Cell Therapy) leading to RPT.", "function": "argue_timing", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "argue_timing", "functionCanon": { "name": "Argue timing (why now)", "slug": "argue_timing", "status": "active", "canonId": "019de52d-16f8-74de-9ec2-900be07d90dd", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 370, "nDataPoints": 0, "notes": "The slide uses a chronological progression of therapeutic classes (Targeted, Immuno-oncology, ADCs, Cell Therapy) leading to RPT.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.527+00", "seconds": 2.766, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/10", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-10", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.7, "x": 0.05, "y": 0.00175 }, "kind": "diagram", "text": "Generational Advancements in Cancer Treatment Have Occurred Categorically...", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da670f56-77c5-434e-ae35-e4477fbab2b5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.7, "x": 0.05, "y": 0.3 }, "kind": "image", "text": "Logos for Rituxan, Herceptin, Avastin, Imbruvica, Keytruda, Tecentriq, Opdivo, Imfinzi, Kadcyla, Enhertu, Padcev, Trodelvy, Abecma, Breyanzi, Kymriah, Yescarta", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a09c36a4-4b7c-40f9-912a-88d8b9350834", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.18, "x": 0.78, "y": 0.004200000000000001 }, "kind": "list", "text": "100 yrs experience through beam therapy; Compelling data; Recent commercial success", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3aca2afe-1a1a-443a-afd2-ae6e310b6e43", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RPT – Positioned to be Next Wave in Cancer Treatment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fef1582-1f49-485a-857d-20191b98eb6e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "97e4b886-4a4a-4eec-86c0-5c93d7788fb5", "evidence": "Chronological progression of cancer treatment modalities", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.527+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "timeline" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 10, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "993d8b01-aa58-414e-8912-0e3cffca5321", "evidence": "The document presents the current market trends and growth opportunity in radiopharmaceuticals.", "position": 1, "objective": "Why is now the right time for RPTs in cancer treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.617297+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 11, "type": "evidence", "title": "The slide uses a comparison table to validate the market potential of the radiopharmaceutical space by highlighting a competitor's success.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 4, "textChars": 330, "nDataPoints": 4, "notes": "The slide uses a comparison table to validate the market potential of the radiopharmaceutical space by highlighting a competitor's success.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.897+00", "seconds": 3.086, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/11", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-11", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.735 }, "kind": "callout", "text": "Radiopharmaceuticals has become a major pillar of growth for Novartis and is gaining recognition across the pharma community", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1ef2a019-62e9-4922-a9ae-2b404761d6f9", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.05, "y": 0.88 }, "kind": "source-note", "text": "(1) Projected 2023 revenue using annualization of 1H 2023 revenue.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "14fdcaaa-98ac-4811-990f-0edfb118bcbc", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Comparison of Lutathera and Pluvicto revenue and commercial footprint", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4ae651b3-b230-4b82-90b0-ffe2648ccffb", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Novartis' Commercial Success with RPT and Broadening Clinical Footprint", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f48a0995-b78f-4e0c-a8bc-e500828f9e8c", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b692bd2c-78d9-4429-8770-96a774fab7a2", "evidence": "Side-by-side comparison of two products across key metrics", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.897+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 11, "frameworkName": "comparison-frame" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 11, "from": 10, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "993d8b01-aa58-414e-8912-0e3cffca5321", "evidence": "The document presents the current market trends and growth opportunity in radiopharmaceuticals.", "position": 1, "objective": "Why is now the right time for RPTs in cancer treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.617297+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "tension", "title": "The slide uses a process flow diagram to show the standard of care progression for two types of NETs.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "balanced", "densityScore": 43, "componentCount": 3, "textChars": 583, "nDataPoints": 1, "notes": "The slide uses a process flow diagram to show the standard of care progression for two types of NETs.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.241+00", "seconds": 5.407, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/12", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-12", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.45, "x": 0.5, "y": 0.2 }, "kind": "diagram", "text": "Management of Advanced/Metastatic, Well-Differentiated SSTR+ NETs. GI-NET and P-NET treatment pathways showing progression from somatostatin analogs to chemotherapy/targeted therapy to 177Lu-DOTATATE.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.241+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "56089057-03eb-4888-9790-8b918858a2cb", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.4, "x": 0.03, "y": 0.2 }, "kind": "paragraph", "text": "Neuroendocrine tumors of the GI tract (GI-NET) and pancreas (P-NET) have limited treatment options. Somatostatin receptor 2 (SSTR2) is expressed in 80-90% of GEP-NETs. Limited FDA approved treatments and invariable disease progression. 177Lu-DOTATATE (Lutathera) approved in 2018 was a major advance for NET patients.", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.241+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdbd6f8b-7d5a-4953-8276-c60455b3f83d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Lead Clinical Indication – Refractory Neuroendocrine Tumors (NETs)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.241+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a5ef4420-63c5-412f-aa75-b1341a208501", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a09cd407-62e9-475a-bb66-ad3b9aa09e53", "evidence": "The slide uses a flow chart to depict the clinical treatment pathway for NET patients.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:22.241+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 12, "frameworkName": "process" } ], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 9, "name": "Problem", "beatId": "c50d4ad9-887f-4c32-8d82-c72b06c2e782", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 12, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "53cf3362-2492-4fd7-a1a1-affed636c3a5", "evidence": "The document highlights the unmet need in NETs and the potential market opportunity.", "position": 0, "objective": "What is the cost of inaction in addressing the unmet need in NETs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.580626+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "tension", "title": "The slide uses a Kaplan-Meier curve to contrast Lutathera against a control group, highlighting the clinical limitation of the current standard of care.", "function": "frame_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "frame_problem", "functionCanon": { "name": "Frame problem", "slug": "frame_problem", "status": "active", "canonId": "019de52d-13db-753e-ad70-e9b2d0dab398", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 6, "textChars": 406, "nDataPoints": 4, "notes": "The slide uses a Kaplan-Meier curve to contrast Lutathera against a control group, highlighting the clinical limitation of the current standard of care.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:24.232+00", "seconds": 7.393, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/13", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-13", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.4, "x": 0.57, "y": 0.45 }, "kind": "callout", "text": "Unprecedented clinical efficacy in Phase 3 trial of Lutathera versus Control. Despite impressive efficacy, all patients invariably progress.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a5eb5a2-d215-4b73-8bde-0b9836ed0314", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.05, "y": 0.2 }, "kind": "chart", "text": "Kaplan-Meier progression-free survival curve", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e753d851-b2f3-4e74-bd83-cdd33d3c6d11", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.1, "x": 0.85, "y": 0.15 }, "kind": "image", "text": "Chemical structure of 177Lu-DOTATATE", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1aba235a-e480-4820-b52b-0e90b5b26b6c", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.05, "y": 0.92 }, "kind": "source-note", "text": "Reference: Strosberg et al, NEJM, 2017", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a25e07ea-f26e-4920-bd16-71d623d3f48c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.3, "x": 0.18, "y": 0.75 }, "kind": "table", "text": "Comparison of patient counts and median PFS for Lutathera vs Control", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4797b9a1-5884-43e0-a0e8-f5d96e7b02e3", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "177Lu (b-isotope) DOTATATE Clinically Effective But Patients Invariably Progress", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "32059685-527a-4606-9c44-324b3da3bd53", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f8bcedb8-8af0-49a1-9958-5d706f17d1b0", "evidence": "Contrasts current clinical success with the inevitable future state of disease progression.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:24.232+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "before-after-framing" } ], "arcBeats": [], "loops": [ { "to": 14, "from": 12, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "53cf3362-2492-4fd7-a1a1-affed636c3a5", "evidence": "The document highlights the unmet need in NETs and the potential market opportunity.", "position": 0, "objective": "What is the cost of inaction in addressing the unmet need in NETs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.580626+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "resolution", "title": "The chart compares median progression vs median survival in months across three patient cohorts (Pancreatic, GI, Overall).", "function": "size_opportunity", "rawType": "why_now", "block": null, "metadata": { "slideType": "why_now", "slideTypeCanon": { "name": "Why now", "slug": "why_now", "status": "active", "canonId": "019de52d-0f2e-718d-b8ad-256dd87582d0", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 4, "textChars": 433, "nDataPoints": 6, "notes": "The chart compares median progression vs median survival in months across three patient cohorts (Pancreatic, GI, Overall).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.788+00", "seconds": 2.623, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/14", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-14", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "callout", "text": "Most NET patients continue to survive 21 to 40 months after progression on Lutathera treatment. Following inevitable disease progression on Lutathera, there are no FDA-approved treatment options", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.788+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "df79ed28-90f9-4375-8cb4-6f75f8326d01", "parentComponentId": null }, { "bbox": { "h": 0.55, "w": 0.9, "x": 0.05, "y": 0.3 }, "kind": "chart", "text": "Median progression and survival in months for Pancreatic, GI, and Overall NET patient groups.", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.788+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "85712079-7304-40e4-b25e-dee736971e7f", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.9 }, "kind": "source-note", "text": "Source: 177Lu+SSA Clinical trial per Brabander et al, Clin Cancer Res 2017", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.788+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3184977f-7bb8-488c-8594-24580484b79b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "NETs – Long Survival Post Progression Provides Unique Market Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.788+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9a341beb-3b0d-483a-b082-8fad91d12d1a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 14, "from": 12, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "53cf3362-2492-4fd7-a1a1-affed636c3a5", "evidence": "The document highlights the unmet need in NETs and the potential market opportunity.", "position": 0, "objective": "What is the cost of inaction in addressing the unmet need in NETs?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.580626+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide uses a chemical structure comparison to illustrate the similarity in binder/chelator while highlighting the difference in radioisotope.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 52, "componentCount": 5, "textChars": 521, "nDataPoints": 0, "notes": "The slide uses a chemical structure comparison to illustrate the similarity in binder/chelator while highlighting the difference in radioisotope.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.961+00", "seconds": 2.754, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/15", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-15", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.4, "x": 0.05, "y": 0.15 }, "kind": "image", "text": "Chemical structures of Lutathera and RYZ101", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5189ce30-a936-498d-95f3-fffb5cbf5206", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.45, "x": 0.51, "y": 0.32 }, "kind": "list", "text": "Evaluate RYZ101 in GEP-NET patients previously treated with 177Lu SSA that have progressed; Use similar dosing schedule frequency; Use clinical trial sites that have experience with Lutathera; IP estate on novel RYZ101 extends to 2042", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2fb9e79a-7c6e-4470-a0c9-b85065a7a6cc", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.4, "x": 0.05, "y": 0.75 }, "kind": "list", "text": "Lutathera and RYZ101 share the same binder and chelator – DOTATATE; RYZ101 has more potent alpha radioisotope 225Ac; Novel proprietary formulation developed on RYZ101", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bdff5faf-eed3-4f34-b629-84e02bd981a4", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.51, "y": 0.27 }, "kind": "paragraph", "text": "Development strategy", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7de78c86-eb01-4a74-94f5-200a7ae8af46", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RYZ101 (225Ac-DOTATATE) – Addresses the Unmet Need in NETs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.961+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40f6aa0a-9305-4a5f-911b-aa0a50277352", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "resolution", "title": "The slide uses a process-oriented layout to show the transition between trial phases.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 738, "nDataPoints": 2, "notes": "The slide uses a process-oriented layout to show the transition between trial phases.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:25.513+00", "seconds": 8.139, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/16", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-16", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.45, "x": 0.03, "y": 0.45 }, "kind": "list", "text": "Phase 1b: Dose de-escalation trial: 17 patients enrolled. Initial and only cohort studied at Phase 3 dose. Assessed DLTs 8 weeks after 1st cycle; No DLTs observed. Primary endpoint is safety. US study. Status: All patients completed dosing; follow-up ongoing", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7bbb599c-aa36-4106-a582-704635a1c50d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.45, "x": 0.52, "y": 0.18 }, "kind": "list", "text": "Key Eligibility Criteria: Progressive disease following treatment with 177Lu SSA (e.g. Lutathera); Age >= 18; Well-differentiated GI-NETs and P-NETs with positive SSTR-PET imaging", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a16d4a76-3e82-4e78-8d6d-446f51ba5d06", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.52, "y": 0.45 }, "kind": "list", "text": "Phase 3: Pivotal trial: Randomized clinical trial of RYZ101 against standard of care (high dose SSA, everolimus, sunitinib). Primary endpoint of progression free survival. Global study. Status: Enrolling now", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e53bd7b0-6fa6-4bf3-9430-12744da6acc3", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.09, "y": 0.34 }, "kind": "paragraph", "text": "ACTINium fOr Neuroendocrine tumors", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "96f21ea2-6000-46ac-993f-88ceb403fd66", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.75, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RYZ101 ACTION-1 Trial: Streamlined Phase 1b to Phase 3 Trial", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.513+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d401de6b-36ef-412e-be06-420a0f8559d6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 17, "type": "analysis", "title": "The table specifically highlights that there were zero treatment-related serious adverse events (SAE) and zero discontinuations.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 42, "componentCount": 3, "textChars": 466, "nDataPoints": 11, "notes": "The table specifically highlights that there were zero treatment-related serious adverse events (SAE) and zero discontinuations.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.451+00", "seconds": 2.928, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/17", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-17", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.3, "x": 0.12, "y": 0.88 }, "kind": "source-note", "text": "AE: adverse event; SAE: serious adverse event. Note: As of June 30, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.451+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92d47f3a-e659-42c2-8912-19725747a189", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.76, "x": 0.12, "y": 0.18 }, "kind": "table", "text": "Adverse Event Category | N=17 (%) | Any AE | 100 | Treatment Related AE | 88.2 | ≥ Grade 3 Related AE | 29.4 | Lymphocyte count decreased | 17.6 | Anemia | 17.6 | Creatinine clearance decreased | 11.8 | Weight decreased | 5.9 | SAE | 35.3 | Treatment Related SAE | 0 | AE leading to dose modification | 23.5 | AE leading to dose discontinuation | 0", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.451+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af19cf87-6318-436f-810e-187fdcc1243a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RYZ101-301 Phase 1b – RYZ101 is Well-Tolerated", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.451+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "904ba48b-961b-4237-869e-bd0ff4e6a469", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 18, "type": "evidence", "title": "Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 69, "componentCount": 6, "textChars": 505, "nDataPoints": 21, "notes": "Waterfall plot displays individual patient responses; benchmarking table compares ORR against historical standards.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.673+00", "seconds": 6.15, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/18", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-18", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.28, "x": 0.68, "y": 0.24 }, "kind": "callout", "text": "5 of 17 patients enrolled (29%) have confirmed objective response per RECIST v1.1", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7dad3ab1-1150-4801-9716-77da87ad5e91", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.6, "x": 0.05, "y": 0.18 }, "kind": "chart", "text": "Max % Change from Baseline, by Investigator", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "af210d65-4863-4d71-81ab-ad89fe7f9d0c", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.03, "y": 0.92 }, "kind": "source-note", "text": "1As of June 30, 2023, by investigator assessment. 2Based on pivotal studies, patients were radiotherapy naïve.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31138838-9ec9-406e-b798-cb07d8b06a4f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.1, "y": 0.85 }, "kind": "source-note", "text": "Efficacy evaluable population are those subjects who received at least one RYZ101 dose and had at least one efficacy evaluable assessment.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6f1efb6c-4e94-4122-a8f8-238cda7bebd2", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.68, "y": 0.44 }, "kind": "table", "text": "Benchmarking ORR: Lutathera 13%, Sunitinib 9%, Everolimus 5%, Octreotide LAR 3%", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "KPI table", "slug": "kpi", "status": "active", "canonId": "019de52d-0324-7799-a84e-d0885a8ad400", "version": 1, "description": null }, "framework": null }, "subkind": "kpi", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3afacd81-4e5f-4d1a-8abe-5e723ef17c31", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.65, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "Phase 1b Preliminary Response Analysis – Best Response", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ae4efd3-feed-45df-b201-1cd7f0913c7d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "9576f9cf-fea9-43f0-831d-194cfbdf36c3", "evidence": "Standard clinical trial efficacy visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:23.673+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 18, "frameworkName": "waterfall-plot" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 19, "type": "evidence", "title": "The chart tracks patient follow-up in weeks, with markers indicating dose, dose reduction, and clinical response (Partial Response, Progressive Disease, Stable ", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 211, "nDataPoints": 18, "notes": "The chart tracks patient follow-up in weeks, with markers indicating dose, dose reduction, and clinical response (Partial Response, Progressive Disease, Stable Disease).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.802+00", "seconds": 2.237, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/19", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-19", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.75, "x": 0.07, "y": 0.18 }, "kind": "chart", "text": "Swimmer plot showing patient treatment duration", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Horizontal bar chart", "slug": "bar-horizontal", "status": "active", "canonId": "019de52c-fec4-7221-986b-1cb5f5e84b1f", "version": 1, "description": null }, "framework": null }, "subkind": "bar-horizontal", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "04135d7b-26bb-4fad-a4b0-812e9d74dd00", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.15, "x": 0.75, "y": 0.65 }, "kind": "legend", "text": "Partial Response, Progressive Disease, Stable Disease, Dose, Dose Reduced", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "174356d2-c5f9-4cfa-a377-9f4c4300ce1d", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.9 }, "kind": "paragraph", "text": "As of June 30, 2023, by investigator assessment", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f688fe9e-1af0-4c80-828a-11bf5299cf4e", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Phase 1b Preliminary Efficacy – Swimmer Plot", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.802+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "229555e4-500b-44ec-8bb6-9869703fd600", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2639f27c-3478-4807-8e48-f5dcf87b5440", "evidence": "Swimmer plot showing patient treatment duration", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:21.312195+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 19, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 20, "type": "setup", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 2, "textChars": 173, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:19.994+00", "seconds": 2.151, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/20", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-20", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.94, "x": 0.03, "y": 0.175 }, "kind": "table", "text": "Comparison table between Lutathera and RYZ101 across status, binder, payload, patient profile, restrictions, and stability.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35dbdff8-c3de-4acb-9ef7-ff8f962a5c13", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RYZ101 in GEP-NETs Shows Promising Characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:19.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dca03bf2-457b-4bf0-8f34-d854a25b910d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Comparison frame", "slug": "comparison-frame", "status": "active", "bestFor": null, "canonId": "019dd9e1-484b-7399-a4fc-d14644b99f93", "version": 1, "bodyDocId": null, "description": "Two or more states/subjects placed side by side to expose a gap.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "e85c7541-e7f4-4f5a-9f79-a7e31dd4d178", "evidence": "Comparison table between Lutathera and RYZ101", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:21.386474+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0088f4dc-c621-4378-af4d-4ef2f5af097c", "evidence": "Direct side-by-side comparison of product attributes to highlight competitive advantage.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:19.994+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 20, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Solution", "beatId": "a134e4cc-5c5e-4ea7-8bd8-6d4ed3346f90", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 21, "type": "resolution", "title": "The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).", "function": "plan_implementation", "rawType": "appendix_methodology", "block": null, "metadata": { "slideType": "appendix_methodology", "slideTypeCanon": { "name": "Appendix methodology", "slug": "appendix_methodology", "status": "active", "canonId": "019de52d-07d9-726c-8599-167f2d2ffaa7", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 415, "nDataPoints": 6, "notes": "The slide uses a standard clinical trial flow diagram (Population -> Treatment -> Endpoints -> Crossover).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.28+00", "seconds": 3.434, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/21", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-21", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "diagram", "text": "Population, Treatment, Endpoints, Crossover", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0b94272c-db20-4e58-8458-84a451f686b2", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.05, "y": 0.28 }, "kind": "list", "text": "Key Eligibility Criteria: Age >= 18, Histologically proven GEP-NETs, Ki-67 <= 20%, Progressive GEP-NET, Stable disease, RECIST v1.1 measurable, ECOG <= 2, CrCl >= 60 mL/min", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "38dbd1bd-2fed-4890-81b2-808b83fb824f", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.2, "x": 0.75, "y": 0.75 }, "kind": "paragraph", "text": "Crossover to RYZ101 at PD (centrally confirmed)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "84e83a60-9ec8-4549-a44d-1128420cd36e", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.75, "y": 0.3 }, "kind": "table", "text": "Statistical Assumptions: N=288, Mean HR=0.62, Power=90%, Critical HR interim=0.680, Critical HR final=0.751, Control arm=10 mo", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b30ee524-6e70-4c39-96a4-d2c6c95e8fd7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.15, "y": 0.05 }, "kind": "title", "text": "RYZ101 Phase 3 Trial Design", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "760b19f6-819c-44b1-92f6-c8895f69f9ac", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1f1cde42-58e3-46d8-afbf-74acb80993c5", "evidence": "List of Key Eligibility Criteria", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:21.461411+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0b1797e5-d20c-4c4d-befb-317fa0500738", "evidence": "Standardized flow of patient population to treatment arms and endpoints", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:21.28+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "clinical-trial-design" } ], "arcBeats": [], "loops": [ { "to": 21, "from": 16, "loop": { "name": "42_hypothesis_test", "slug": "42-hypothesis-test", "status": "active", "bestFor": "Strategy validation, due diligence, research presentations", "canonId": "019dd956-76fd-7577-8bcd-d7d39f7c13a8", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence", "familyLabel": null }, "matchId": "dd065b7b-77b8-4f37-837e-80ec7e755de5", "evidence": "The document presents clinical trial results for RYZ101, including Phase 1b preliminary response analysis and efficacy data.", "position": 2, "objective": "How does RYZ101 perform in clinical trials?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:37:55.651027+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 22, "type": "resolution", "title": "The slide uses a three-column layout to break down the market opportunity into patient population, pricing, and launch dynamics.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 81, "componentCount": 8, "textChars": 577, "nDataPoints": 8, "notes": "The slide uses a three-column layout to break down the market opportunity into patient population, pricing, and launch dynamics.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:25.801+00", "seconds": 7.722, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/22", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-22", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.28, "x": 0.67, "y": 0.25 }, "kind": "chart", "text": "Rapid Lutathera market uptake ($M)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f067170-dbf2-4a1a-ae0f-000b3df95531", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.28, "x": 0.67, "y": 0.55 }, "kind": "list", "text": "RYZ101 launch considerations: No other approved therapies, Up to 4 doses over 6 months, Target accounts have experience with RPT", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10caf775-1422-4c62-b433-542af5489bd6", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.25, "x": 0.38, "y": 0.45 }, "kind": "list", "text": "RYZ101 premium features: Later line of treatment, Improved potency w/225Ac, Easier drug handling", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab1d63a3-2788-4a99-a585-c5402736a1df", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.3, "x": 0.05, "y": 0.18 }, "kind": "paragraph", "text": "Addressable Patient Population", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "66f1a774-2dbe-443c-9844-0d3e3552c6b2", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.7, "y": 0.18 }, "kind": "paragraph", "text": "Launch Dynamics", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c60ff69-beef-407a-9165-e8e56cf4b674", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.38, "y": 0.18 }, "kind": "paragraph", "text": "Pricing / Treatment (US) (2)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f6848b35-acd9-4ae3-9a7e-204bf173efec", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.6, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "(1) Based on internal estimates. (2) Per treatment includes standard 4 doses for Lutathera and standard 6 doses for Pluvicto. (3) Projected 2023 revenue using annualization of 1H 2023 revenue.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a76f85c7-a269-4afa-bef6-d6238ce353c4", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.75, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "RYZ101 GEP-NETS is a Meaningful Commercial Opportunity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:25.801+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "54feb06b-cd4e-427a-823c-665911112de6", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Market Segmentation Pyramid", "slug": "market-segmentation-pyramid", "status": "active", "bestFor": null, "canonId": "1c9f3543-c96f-4a5b-b4a4-9b2a412c0aaf", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "a0b15f38-17e3-4bba-85e2-268a7cb2b6bc", "evidence": "Addressable Patient Population", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:32:21.536378+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 22, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 22, "name": "Market Sizing", "beatId": "4eb5bdc2-46df-4e7d-90bc-1dad24a39c2b", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "The document provides market sizing information for RYZ101 in GEP-NETS.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 23, "type": "appendix", "title": "The slide highlights that 47% of SCLC samples show some level of SSTR2 expression, with 27% showing high expression.", "function": "analyze_data", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 5, "textChars": 285, "nDataPoints": 4, "notes": "The slide highlights that 47% of SCLC samples show some level of SSTR2 expression, with 27% showing high expression.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.191+00", "seconds": 3.06, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/23", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-23", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.6, "x": 0.2, "y": 0.85 }, "kind": "callout", "text": "SSTR2 expression appears to be distinct from DLL3 expression in SCLC tumors", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b94c4245-590d-4efe-b338-25c8235b4539", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.3, "x": 0.35, "y": 0.35 }, "kind": "chart", "text": "Pie chart showing SSTR2 expression distribution in 70 SCLC samples", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Pie chart", "slug": "pie", "status": "active", "canonId": "019de52c-ffdb-71bb-a800-5c5ab9f1c373", "version": 1, "description": null }, "framework": null }, "subkind": "pie", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f60f68ce-9c5d-4fa4-bd62-2196abd06770", "parentComponentId": null }, { "bbox": { "h": 0.75, "w": 0.2, "x": 0.03, "y": 0.15 }, "kind": "image", "text": "Immunohistochemistry images of SCLC samples", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2abfab56-48d7-4cdc-9b1a-e656b75ce439", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.2, "x": 0.75, "y": 0.15 }, "kind": "image", "text": "Control images: Normal lung and Pancreatic NET", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f9b9147-1e99-4e62-9863-762a6eeae769", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "SSTR2 is Overexpressed in Small Cell Lung Cancer (SCLC)", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.191+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "297c2518-7b71-4adf-83cb-da0652e2e3e4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Figure-Ground Relationship", "slug": "figure-ground-relationship", "status": "active", "bestFor": null, "canonId": "019dd956-d087-741f-b358-1303dd35483e", "version": 1, "bodyDocId": null, "description": "Perception organizes into figure (focus) and ground (background)", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Designer", "layer": "slide", "agents": [ "Designer" ], "matchId": "ead18fee-1850-4cb1-b6d7-c5fcae7e2142", "evidence": "SSTR2 expression appears to be distinct from DLL3 expression in SCLC tumors", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:32:21.609234+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 23, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "evidence", "title": "Includes a visual case study with PET scan images showing tumor reduction.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 44, "componentCount": 4, "textChars": 344, "nDataPoints": 12, "notes": "Includes a visual case study with PET scan images showing tumor reduction.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.288+00", "seconds": 5.057, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/24", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-24", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.6, "x": 0.2, "y": 0.6 }, "kind": "image", "text": "PET scan before and after treatment", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.288+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e4d4317-7597-40b1-a77c-8bc3f0587eb4", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.4, "x": 0.05, "y": 0.48 }, "kind": "paragraph", "text": "Case example: 74 yo female, refractory to chemotherapy. Treated with 5 cycles of 177Lu DOTATATE -> PFS 766 days, OS 907 days", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.288+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "19a9679a-e469-4817-aed5-e488238d7f6f", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "table", "text": "Publication, # patients, Imaging results, Treatment, Response, Survival for von Hinten et al and Kim et al", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.288+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a389386-9346-44cb-9ca4-a140d5b99d20", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Early Third-Party Clinical Data with 68Ga and 177Lu DOTATATE in Refractory SCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.288+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47d32144-6d81-4ac8-9e31-b25df6466e92", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "evidence", "title": "The chart shows tumor growth over 57 days across four treatment groups, with the combination therapy (green line) demonstrating the most effective tumor suppres", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 37, "componentCount": 4, "textChars": 196, "nDataPoints": 40, "notes": "The chart shows tumor growth over 57 days across four treatment groups, with the combination therapy (green line) demonstrating the most effective tumor suppression.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.936+00", "seconds": 2.678, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/25", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-25", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.4, "x": 0.55, "y": 0.15 }, "kind": "chart", "text": "Mean Tumor Volume over 57 days", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.936+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5530c31d-63e4-48e8-afb3-4c8e3847ea0f", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.05, "y": 0.45 }, "kind": "diagram", "text": "Treatment Groups: Vehicle, Chemo, 225Ac DOTATATE, Combo", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.936+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7dc24061-8f50-4700-bb2b-041b9034803a", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.35, "x": 0.05, "y": 0.15 }, "kind": "image", "text": "H69 Cell Line (SSTR2+) mice and SSTR2 IHC image", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.936+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5e54590a-5f72-4634-9bcc-aad308af5ddf", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "ES-SCLC Preclinical Studies of RYZ101 Combined with Chemotherapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.936+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03895d4a-c34c-4b21-b455-7a88473a6c1a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "appendix", "title": "The slide outlines a clinical trial protocol for a combination therapy involving RYZ101, chemotherapy, and PD-L1 inhibitors.", "function": "plan_implementation", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 6, "textChars": 599, "nDataPoints": 1, "notes": "The slide outlines a clinical trial protocol for a combination therapy involving RYZ101, chemotherapy, and PD-L1 inhibitors.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.528+00", "seconds": 3.174, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/26", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-26", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.03, "w": 0.4, "x": 0.05, "y": 0.9 }, "kind": "disclaimer", "text": "*PD-L1i is atezolizumab (drug product being supplied by Genentech/Roche)", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a51b2263-795e-4df4-a07b-71c7c3ab1c81", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.8, "x": 0.1, "y": 0.35 }, "kind": "image", "text": "Patient selection process diagram", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2e248eea-f5af-4f4d-9395-b30921c2d6b1", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.9, "x": 0.05, "y": 0.15 }, "kind": "list", "text": "Target patient population: extensive stage small cell lung cancer (ES-SCLC)\nLine of therapy: First line\nPatient selection: SSTR2 PET imaging to select patients where at least 50% of tumors overexpress SSTR2", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "491ca67c-ab58-48dd-83d8-11e9921033d0", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.9, "x": 0.05, "y": 0.6 }, "kind": "list", "text": "Treatment regimen:\nRYZ101 with SOC (platinum/etoposide chemotherapy and PD-L1i*)\nRYZ101 to undergo dose escalation and target total of 6 cycles of treatment\nAssess durability of response", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c230b7f5-fa84-4038-8812-e57572eff603", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.3, "x": 0.05, "y": 0.82 }, "kind": "paragraph", "text": "Status: U.S. study – enrolling now", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "614d5e48-751f-470e-bbef-c162d555808b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RYZ101 Phase 1b Trial in First Line Combination Treatment of ES-SCLC", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.528+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f3672f9b-7142-4618-bf7f-2c12c4437a59", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Audience Definition", "slug": "audience-definition", "status": "active", "bestFor": null, "canonId": "019dd956-7f2a-775d-aeee-ff099bcb7756", "version": 1, "bodyDocId": null, "description": "Six key questions: Who are they? What do they know? What do they believe? What do they care about? What do they fear? What decisions can they make?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Storyteller", "layer": "slide", "agents": [ "Storyteller" ], "matchId": "69213300-7ea1-46ca-be72-03beba61b9da", "evidence": "Target patient population: extensive stage small cell lung cancer (ES-SCLC)", "pageRefs": null, "priority": "Core", "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:32:21.759166+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 26, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "resolution", "title": "Includes PET scan imagery and a pharmacokinetic tumor uptake graph comparing RAYZ-SSTR to DOTATATE.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 424, "nDataPoints": 20, "notes": "Includes PET scan imagery and a pharmacokinetic tumor uptake graph comparing RAYZ-SSTR to DOTATATE.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.068+00", "seconds": 3.594, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/27", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-27", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.25, "w": 0.38, "x": 0.49, "y": 0.52 }, "kind": "chart", "text": "Tumor uptake graph showing %ID/g over time (h)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.068+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c2087f94-30c3-4d70-a156-40c2af77a71b", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.52, "x": 0.41, "y": 0.18 }, "kind": "image", "text": "PET scan comparison of DOTATATE and RAYZ-SSTR", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.068+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1dc67714-9086-4544-9979-52346df63b2c", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.35, "x": 0.03, "y": 0.55 }, "kind": "list", "text": "Novel SSTR2 binder opportunities: Extend revenue opportunity for RYZ101 in additional indications, if approved; Intend to expand into earlier lines of therapy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.068+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05aa61cd-7251-4355-8858-a436d3a978b3", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.35, "x": 0.03, "y": 0.2 }, "kind": "list", "text": "Novel SSTR2 binder discovery progress: Multiple novel chemical series being explored in parallel; Several leads show improved profile over DOTATATE", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.068+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "13823a2b-d413-4af9-94ab-b9d66d14eb73", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "SSTR2 – Lifecycle Management", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.068+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "83944100-28f7-4c04-853d-84295a5ab0be", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "HFS Horizons", "slug": "hfs-horizons", "status": "active", "bestFor": null, "canonId": "019de52d-1a8a-70de-a683-cfc294ece899", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "2b9f34c1-0ee0-4735-8ff4-3201f53b6c81", "evidence": "Novel SSTR2 binder opportunities: Extend revenue opportunity for RYZ101 in additional indications", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.6, "extraction": { "at": "2026-07-17 00:32:21.834048+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 27, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "appendix", "title": "CMC stands for Chemistry, Manufacturing, and Controls. The slide highlights infrastructure investment and current CDMO reliance.", "function": "present_solution", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 3, "textChars": 397, "nDataPoints": 2, "notes": "CMC stands for Chemistry, Manufacturing, and Controls. The slide highlights infrastructure investment and current CDMO reliance.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:20.819+00", "seconds": 2.206, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/28", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-28", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.6, "x": 0.38, "y": 0.28 }, "kind": "image", "text": "Architectural rendering of the RayzeBio facility", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.819+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7388319e-dc74-45f9-96d6-2675228d58fe", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.35, "x": 0.03, "y": 0.25 }, "kind": "list", "text": "63,000 sq. ft. facility in Indianapolis; Designed to support development and commercial scale manufacturing; Expected to be operational by end of 2023; Planned 225Ac manufacturing by end of 2024; Third party manufacturer 225Ac supply agreements in place; RYZ101 currently manufactured by CDMO partner", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.819+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "864c04ff-0f9d-4608-9b47-56098de638b4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Investing in Seamless CMC – RayzeBio GMP Facility", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:20.819+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d4e3bfd-c4ea-4a98-8558-47d6bf4d1f61", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Information architecture", "slug": "information-architecture", "status": "active", "bestFor": null, "canonId": "643f994f-1fa5-4c17-8dfe-aa33e091b6aa", "version": 1, "bodyDocId": null, "description": "Wayfinding, scannability, scent, F-pattern, banner blindness.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "1547f501-0560-4aea-854b-9c702c63ae0f", "evidence": "63,000 sq. ft. facility in Indianapolis; Designed to support development and commercial scale manufacturing", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 00:32:21.908321+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 28, "whyItWorks": null, "antipattern": null, "cardinality": "optional", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 29, "type": "resolution", "title": "The workflow includes a feedback loop from in vivo screening back to binder discovery.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "balanced", "densityScore": 48, "componentCount": 4, "textChars": 492, "nDataPoints": 1, "notes": "The workflow includes a feedback loop from in vivo screening back to binder discovery.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.474+00", "seconds": 2.683, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/29", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-29", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.55, "x": 0.4, "y": 0.15 }, "kind": "diagram", "text": "Target Selection -> Binder discovery and optimization -> In vitro screening -> X-ray crystallography -> Linker exploration and optimization -> Radiolabeling optimization -> In vivo screening", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0969d4fc-4244-4d4b-9710-96eedb40e4da", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.3, "x": 0.03, "y": 0.2 }, "kind": "list", "text": "28,000 sq ft R&D center in San Diego: Alpha and beta isotope radiolabeling lab, Vivarium with molecular imaging, Full in vitro biological capabilities, Internal small molecule and peptide chemistry, DMPK suite", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef063138-2d16-4d1b-a84f-ab78f5da2dda", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.09 }, "kind": "paragraph", "text": "Over 500 in vivo experiments completed", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e6fbe93e-679a-4c2d-802c-283561be58b6", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Data-Driven Discovery Workflow from RayzeBio R&D Center", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9d148a67-d5f1-4bbb-a02d-be81890a9a94", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "d8b4a52d-ebfb-4382-94ce-8b280d237c3a", "evidence": "Target Selection -> Binder discovery and optimization -> In vitro screening -> X-ray crystallography -> Linker exploration and optimization -> Radiolabeling optimization -> In vivo screening", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.8, "extraction": { "at": "2026-07-17 00:32:21.984249+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "a4e6851d-00d0-40f2-858e-3eaafd0a1b2a", "evidence": "Sequential workflow diagram", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:21.474+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 29, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 30, "type": "resolution", "title": "The slide uses a staircase-style diagram to represent progression in clinical relevance of data.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 18, "componentCount": 3, "textChars": 173, "nDataPoints": 0, "notes": "The slide uses a staircase-style diagram to represent progression in clinical relevance of data.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:21.943+00", "seconds": 2.324, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/30", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-30", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.85, "x": 0.08, "y": 0.18 }, "kind": "diagram", "text": "Staircase process flow from Pre-clinical to Clinical development", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.943+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31befb1f-d11d-4bfb-98a8-0ae629df4a3f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.2, "x": 0.75, "y": 0.85 }, "kind": "disclaimer", "text": "ILLUSTRATIVE ONLY actual development plans may vary", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.943+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7292672a-30d1-4276-9073-cd8cbc068e3f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RayzeBio Stepwise Approach for Clinical Development in RPT", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:21.943+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bad39801-5090-4138-93d1-d7c64679e893", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "a577a4ba-f57a-4f38-8229-91f097c4bb98", "evidence": "Staircase diagram showing sequential development stages", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:21.943+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 30, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 31, "type": "resolution", "title": "Includes IHC staining images and a waterfall plot showing tumor shrinkage.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 529, "nDataPoints": 1, "notes": "Includes IHC staining images and a waterfall plot showing tumor shrinkage.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:26.246+00", "seconds": 6.587, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/31", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-31", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.94, "x": 0.03, "y": 0.35 }, "kind": "callout", "text": "LEAD INDICATION: HCC | Other potential indications: Prostate, Lung Squamous, Ovarian, Thyroid", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.246+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a0e41884-4adb-4928-8a68-fb33a6abcc5d", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.42, "x": 0.53, "y": 0.55 }, "kind": "chart", "text": "Best Tumour Shrinkage (per RECIST v1.1)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Waterfall chart", "slug": "waterfall", "status": "active", "canonId": "019de52d-002e-733e-b5cf-dd3beb6692cc", "version": 1, "description": null }, "framework": null }, "subkind": "waterfall", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.246+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc2e6087-4bf9-408b-b698-d671375eb2f2", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.42, "x": 0.05, "y": 0.55 }, "kind": "image", "text": "IHC staining images of HCC vs Normal liver", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.246+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3b2ac105-d175-4bc8-abde-11caacb1814b", "parentComponentId": null }, { "bbox": { "h": 0.13, "w": 0.94, "x": 0.03, "y": 0.16 }, "kind": "paragraph", "text": "Main attractive features: Oncofetal protein, expressed in various fetal tissues but not detected in normal postnatal tissue; Expressed in hepatocellular cancer (HCC) in up to 75% of cases, associated with worse prognosis; Emerging clinical data with GPC3 CAR-T indicate objective response in HCC", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.246+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fdc42f9d-54db-45b9-bdb1-653c71521711", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.78, "x": 0.03, "y": 0.04 }, "kind": "title", "text": "Glypican-3 (GPC3): Novel Peptide Targeted for Cancer Therapy", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.246+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fe34fba-51d8-4a54-81c0-8312c1da4c06", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Waterfall chart", "slug": "waterfall-chart", "status": "active", "bestFor": null, "canonId": "e2799da3-725f-44a9-a093-570f1f388e64", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "0ba7743c-6153-41d4-97c3-92c2a5250828", "evidence": "chart/waterfall: Best Tumour Shrinkage (per RECIST v1.1)", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:10.850323+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 31, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 32, "type": "resolution", "title": "The slide demonstrates the efficacy and specificity of the drug candidate in a preclinical model.", "function": "present_solution", "rawType": "solution", "block": null, "metadata": { "slideType": "solution", "slideTypeCanon": { "name": "Solution", "slug": "solution", "status": "active", "canonId": "019de52d-0eb5-72ff-8b70-ba70a4199282", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 6, "textChars": 296, "nDataPoints": 16, "notes": "The slide demonstrates the efficacy and specificity of the drug candidate in a preclinical model.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.835+00", "seconds": 2.906, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/32", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-32", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.65, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Biodistribution %ID/g across organs over 24h, 48h, 96h, 192h", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7f2ddb1-82f4-4632-8706-1866b838de86", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.2, "x": 0.35, "y": 0.35 }, "kind": "image", "text": "SPECT Imaging (96 hrs)", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1426189c-fec6-4a35-ba3b-f69bd2e2e2b7", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.1, "y": 0.17 }, "kind": "list", "text": "KD = 0.7 nM, Rapid internalization, Cross species binding", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "03111103-7873-4941-a1a7-78aac16416b1", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.15, "x": 0.72, "y": 0.32 }, "kind": "table", "text": "Tumor: Kidney ratio table", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d08213e4-d7f7-45fd-a062-77708bd2d007", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Prolonged tumor retention with minimal normal tissue binding using 177Lu", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9efce390-e81a-48bc-b937-b94e3a2b8352", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "GPC3 Drug Candidate Biodistribution in HepG2 Xenograft Model", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.835+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "10f82998-d4a6-4a90-ba54-de279bcfa258", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 33, "type": "evidence", "title": "Comparison of 225Ac vs 177Lu efficacy at significantly different dose levels.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 30, "componentCount": 3, "textChars": 273, "nDataPoints": 3, "notes": "Comparison of 225Ac vs 177Lu efficacy at significantly different dose levels.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.598+00", "seconds": 2.56, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/33", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-33", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.7, "w": 0.55, "x": 0.05, "y": 0.15 }, "kind": "chart", "text": "Hep3B2.1-7 (Low GPC3 Expresser) Tumor Model", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.598+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "541c0b15-af3c-41ee-8937-395c6fc8394b", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.65, "y": 0.3 }, "kind": "list", "text": "Single doses of 177Lu and 225Ac labelled RYZ801 show significant tumor inhibition. 225Ac has demonstrated better results than 177Lu at a doses that are 1,000 times lower", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.598+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2699e15a-ba0b-4828-a28c-c0c886bbf999", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "RYZ801 Preclinical Results in HCC Model with Single Treatment", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.598+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4820a45f-3aee-44a9-b023-025af3d94505", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 34, "type": "evidence", "title": "Includes clinical imaging examples for two patients.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 5, "textChars": 353, "nDataPoints": 2, "notes": "Includes clinical imaging examples for two patients.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.772+00", "seconds": 2.626, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/34", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-34", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.43, "x": 0.53, "y": 0.45 }, "kind": "image", "text": "Patient B PET scans", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a8b9a64-54c4-4fb8-b58f-0bf6fbeb85be", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.04, "y": 0.45 }, "kind": "image", "text": "Patient A CT and PET scans", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dcbe002c-e8a2-4fd5-9a88-81d2b753b2a9", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.94, "x": 0.03, "y": 0.15 }, "kind": "list", "text": "47 HCC patients imaged using 68Ga labeled RayzeBio binder at 1-2 hrs post injection\nTumor uptake of binder observed in approximately 90% of patients. Heterogenous uptake across lesions in a minority of patients.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "33c995ce-d3d2-4eca-8da3-e3da02a21c8b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.15, "x": 0.03, "y": 0.88 }, "kind": "source-note", "text": "Note: As of August 1, 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "371c5f45-9bc8-46b8-a2c9-98a6ca46041a", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.94, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Compassionate Use – Early Human Imaging with 68Ga Confirms Tumor Uptake", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.772+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1dd5a348-6b2d-46fb-a881-e2590556b811", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 35, "type": "evidence", "title": "The slide uses a longitudinal imaging sequence to demonstrate drug efficacy/retention.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 433, "nDataPoints": 0, "notes": "The slide uses a longitudinal imaging sequence to demonstrate drug efficacy/retention.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.553+00", "seconds": 3.368, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/35", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-35", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "callout", "text": "Patient A underwent additional imaging with low dose 177Lu labeled RayzeBio GPC3 binder", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "99da5f62-14de-4e16-8af5-6ab0726e4fac", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.45, "x": 0.05, "y": 0.028 }, "kind": "image", "text": "Three-panel longitudinal PET/SPECT scan sequence at 24h, 96h, and 196h showing HCC tumor retention.", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "94581654-4d3b-4d81-838f-01eaee97c631", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.35, "x": 0.58, "y": 0.04 }, "kind": "list", "text": "Next steps: Continue extended imaging for additional patients; Use extended imaging data to calculate dosimetry; Consider compassionate use treatment (225Ac or 177Lu) for certain patients", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "274103b8-f7ab-4c10-9add-0e11af701312", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.8, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Extended Imaging Timepoints with 177Lu Shows Tumor Retention", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.553+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "686103b0-a623-41b3-ac89-e79e0a5e91bc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 36, "type": "resolution", "title": "The slide uses a process flow diagram to illustrate the regulatory and clinical milestones.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 21, "componentCount": 3, "textChars": 224, "nDataPoints": 0, "notes": "The slide uses a process flow diagram to illustrate the regulatory and clinical milestones.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.771+00", "seconds": 2.473, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/36", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-36", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.5, "w": 0.95, "x": 0.02, "y": 0.2 }, "kind": "diagram", "text": "Process flow from Compassionate Use and IND enabling studies to IND filing and Phase 1", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.771+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6254164d-0458-4b1f-bc05-af0a8b5d1fe8", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.5, "x": 0.25, "y": 0.075 }, "kind": "list", "text": "RYZ801 (therapeutic) – GPC3 binder with 225Ac\nRYZ811 (diagnostic) – GPC3 binder with 68Ga", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.771+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5b76e304-12fe-43c2-a39e-55d555f1233f", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "GPC3 Program – Next Steps for Clinical Evaluation", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.771+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8fe58e0d-07ee-4bce-bc36-891563174afb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "f2b4c7fa-9233-4ea1-88c3-2a86a477963e", "evidence": "The slide uses a flow diagram to show the sequence of clinical development steps.", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 11:31:22.771+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 36, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 37, "type": "evidence", "title": "The slide lists 24 investor logos/names.", "function": "show_traction", "rawType": "traction", "block": null, "metadata": { "slideType": "traction", "slideTypeCanon": { "name": "Traction", "slug": "traction", "status": "active", "canonId": "019de52d-0edd-72ab-820f-3ebc71a9c542", "version": 1, "description": null }, "function": "show_traction", "functionCanon": { "name": "Show traction", "slug": "show_traction", "status": "active", "canonId": "019de52d-16a8-756a-9b38-a7d35420561d", "version": 1, "description": null }, "density": "balanced", "densityScore": 38, "componentCount": 4, "textChars": 257, "nDataPoints": 5, "notes": "The slide lists 24 investor logos/names.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.001+00", "seconds": 2.696, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/37", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-37", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.47, "x": 0.48, "y": 0.15 }, "kind": "callout", "text": "Q2 '23 Cash, cash equivalents and short term investments: ~$257M", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d8215f8-83a5-4080-b2c6-33c65376f939", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.9, "x": 0.05, "y": 0.4 }, "kind": "image", "text": "Investor logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c12804bf-fa75-47d3-ab48-3686eb07ecb4", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.4, "x": 0.05, "y": 0.15 }, "kind": "paragraph", "text": "Total equity capital of $418M raised\n• $45M Series A – August 2020\n• $105M Series B – November 2020\n• $108M Series C – June 2021\n• $160M Series D – September 2022", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ce781dfa-39ad-431e-bb22-6b16cc63a82b", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Financing History", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.001+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a1f6ef88-8708-4c98-8f30-057fa896d0de", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 38, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 8, "componentCount": 2, "textChars": 92, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.374+00", "seconds": 2.054, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/38", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-38", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.95, "x": 0.03, "y": 0.15 }, "kind": "framework", "text": "Gantt chart style roadmap", "attrs": null, "canon": { "kind": { "name": "Framework", "slug": "framework", "status": "active", "canonId": "019de52c-fa18-77c6-b10a-ccb8277ac0fa", "version": 1, "description": "Named conceptual framework instance." }, "tool": null, "subkind": { "name": "Framework instance", "slug": "instance", "status": "active", "canonId": "019de52d-05a2-72af-be0b-7edc60708a03", "version": 1, "description": null }, "framework": null }, "subkind": "instance", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49803c1a-2c35-40c9-862a-6ac47ef325a5", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.85, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "Purposeful Execution Leading to Anticipated Milestones Through 2025", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ba6db30-229b-4195-88ba-aebe8c1f3fd5", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Gantt chart", "slug": "gantt-chart", "status": "active", "bestFor": null, "canonId": "019de52d-1fa2-7206-bb14-bb9ff5fccdba", "version": 1, "bodyDocId": null, "description": null, "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "16692f74-b4d9-494d-bdc5-442458cc81bb", "evidence": "framework/instance: Gantt chart style roadmap", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:32:11.156322+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [ { "matchId": "010a8748-543d-43e6-a621-f8ad8df4b31f", "evidence": "Timeline-based project management visualization", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 11:31:22.374+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 38, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 39, "type": "setup", "title": "Includes 88 FTEs count and board member list.", "function": "other", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "other", "functionCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-15e1-75bc-99dc-07732380e2ce", "version": 1, "description": null }, "density": "dense", "densityScore": 53, "componentCount": 6, "textChars": 269, "nDataPoints": 1, "notes": "Includes 88 FTEs count and board member list.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:22.798+00", "seconds": 2.466, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/39", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-39", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.95, "x": 0.03, "y": 0.2 }, "kind": "image", "text": "Management team headshots", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "921124eb-02cc-48f0-80ae-dcc1b8d2c8b2", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.95, "x": 0.03, "y": 0.2 }, "kind": "list", "text": "Management team bios and credentials", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "05c3c9d6-88f2-4df4-8ad4-1caf16ae7b7c", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.95, "x": 0.03, "y": 0.75 }, "kind": "list", "text": "Board of Directors list", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc93fe7d-e368-436b-a204-bf0d018fd00b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.3, "x": 0.03, "y": 0.09 }, "kind": "paragraph", "text": "88 FTEs¹ across 2 main sites (San Diego, Indianapolis)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f2200ecb-7284-45fa-8ebf-0dd4b30e5cdc", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.03, "y": 0.9 }, "kind": "source-note", "text": "¹As of June 30, 2023 ²Director to transition off board in connection with the IPO", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "717ba8a9-da28-420f-8b94-bd9952fc6bea", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.03, "y": 0.03 }, "kind": "title", "text": "Experienced and Entrepreneurial Life Sciences Team", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:22.798+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7236ee64-4e4a-4846-a0d8-733ec14d36e6", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 39, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 39, "name": "Team", "beatId": "b1b90c07-22d7-4572-9e13-314d9970d9bb", "matchId": "2379836a-8c99-4f5d-ad21-87e4f467e25b", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "The document presents information about RayzeBio's experienced and entrepreneurial life sciences team.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 40, "type": "setup", "title": "The slide uses a vertical process flow to illustrate vertical integration.", "function": "present_solution", "rawType": "unfair_advantage", "block": null, "metadata": { "slideType": "unfair_advantage", "slideTypeCanon": { "name": "Unfair advantage", "slug": "unfair_advantage", "status": "active", "canonId": "019de52d-0f56-744f-8bb4-c8a8cca240d6", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 54, "componentCount": 4, "textChars": 647, "nDataPoints": 3, "notes": "The slide uses a vertical process flow to illustrate vertical integration.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:23.336+00", "seconds": 2.9, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/40", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-40", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.65, "w": 0.25, "x": 0.03, "y": 0.27 }, "kind": "diagram", "text": "Discovery, Early Development, Clinical Development, Manufacturing, Capitalization", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c1b16cc-2be7-48d6-a969-2a3102637af2", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.65, "x": 0.3, "y": 0.27 }, "kind": "list", "text": "Specialized RPT research facility (28,000 sq ft) with 500+ in vivo studies completed\nMultiple proprietary development candidates for various solid tumor indications\n225Ac clinical program in Phase 3 for GEP-NETs and in Phase 1b for SCLC\nConstructing a centralized GMP facility to supply drug product; Redundant 225Ac supply\nWell capitalized from broad set of investors", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72b53074-6152-45de-be88-81be95077919", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.95, "x": 0.03, "y": 0.15 }, "kind": "paragraph", "text": "We are building a vertically integrated company with RPT capabilities utilizing 225Ac spanning discovery to late-stage development to GMP manufacturing", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3fcdbbd7-db80-4d30-9629-6fd4be659835", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.03, "y": 0.05 }, "kind": "title", "text": "RayzeBio – Uniquely Positioned in the RPT Space", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "387ac6b7-8df0-4c83-a643-4655f483ccd2", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "367b7cdf-c650-4242-814a-8fce22db400b", "evidence": "The slide maps the company's activities from discovery to manufacturing as a vertical integration strategy.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 11:31:23.336+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 40, "frameworkName": "value-chain" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 41, "type": "setup", "title": "This is a closing or transition slide featuring the company logo and mission statement.", "function": "inspire_vision", "rawType": "mission", "block": null, "metadata": { "slideType": "mission", "slideTypeCanon": { "name": "Mission", "slug": "mission", "status": "active", "canonId": "019de52d-0fce-7496-b34c-18fd6a6e3310", "version": 1, "description": null }, "function": "inspire_vision", "functionCanon": { "name": "Inspire vision", "slug": "inspire_vision", "status": "active", "canonId": "019de52d-16d0-7756-83de-376eeac6fa40", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 133, "nDataPoints": 0, "notes": "This is a closing or transition slide featuring the company logo and mission statement.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 11:31:26.292+00", "seconds": 5.793, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de075-dd1e-7468-9323-d12fde1b7732/41", "deck": "/decks/019de075-dd1e-7468-9323-d12fde1b7732", "deckAnchor": "/decks/019de075-dd1e-7468-9323-d12fde1b7732#slide-41", "deckJson": "/decks/019de075-dd1e-7468-9323-d12fde1b7732.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.38, "x": 0.31, "y": 0.33 }, "kind": "image", "text": "RayzeBio", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.292+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5091d552-31d1-4133-a56f-c393c4be5f46", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.7, "x": 0.15, "y": 0.62 }, "kind": "paragraph", "text": "Improving cancer patient survival by efficiently developing targeted innovative drugs that harness the power of radioisotopes", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 11:31:26.292+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7fe1c458-606e-47e7-8126-692cd9ad269f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 9, "to": 12, "label": "Problem", "description": "The document presents the problem statement, highlighting the limitations of current cancer treatments and the unmet need in NETs." }, { "from": 15, "to": 20, "label": "Solution", "description": "The document presents RYZ101 as a solution to the unmet need in NETs, highlighting its promising characteristics and clinical trial results." }, { "from": 22, "to": 22, "label": "Market Sizing", "description": "The document provides market sizing information for RYZ101 in GEP-NETS." }, { "from": 39, "to": 39, "label": "Team", "description": "The document presents information about RayzeBio's experienced and entrepreneurial life sciences team." } ], "loops": [ { "from": 12, "to": 14, "label": "Cost Of Inaction", "description": "What is the cost of inaction in addressing the unmet need in NETs?" }, { "from": 10, "to": 11, "label": "Why Now", "description": "Why is now the right time for RPTs in cancer treatment?" }, { "from": 16, "to": 21, "label": "Hypothesis Test", "description": "How does RYZ101 perform in clinical trials?" } ] }